2015
DOI: 10.1089/neu.2014.3706
|View full text |Cite
|
Sign up to set email alerts
|

Sulfonylurea Receptor 1 in Humans with Post-Traumatic Brain Contusions

Abstract: Post-traumatic brain contusions (PTBCs) are traditionally considered primary injuries and can increase in size, generate perilesional edema, cause mass effect, induce neurological deterioration, and cause death. Most patients experience a progressive increase in pericontusional edema, and nearly half, an increase in the hemorrhagic component itself. The underlying molecular pathophysiology of contusion-induced brain edema and hemorrhagic progression remains poorly understood. The aim of this study was to inves… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

5
42
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 43 publications
(47 citation statements)
references
References 50 publications
5
42
0
Order By: Relevance
“…Sur1 is a key regulatory protein involved in CE generation in multiple CNS disorders including TBI and ischemic stroke[79,15]. Sur1 expression has been demonstrated in human contusional tissue[28]. We have exciting preliminary data suggesting human CSF Sur1 levels are undetectable in non-injured controls, elevated in patients with sTBI, and trajectories may correlate with CE and outcomes ( In Press , Critical Care Medicine, abstract presented at American Academy of Neurology, 2016[29]).…”
Section: Discussionmentioning
confidence: 99%
“…Sur1 is a key regulatory protein involved in CE generation in multiple CNS disorders including TBI and ischemic stroke[79,15]. Sur1 expression has been demonstrated in human contusional tissue[28]. We have exciting preliminary data suggesting human CSF Sur1 levels are undetectable in non-injured controls, elevated in patients with sTBI, and trajectories may correlate with CE and outcomes ( In Press , Critical Care Medicine, abstract presented at American Academy of Neurology, 2016[29]).…”
Section: Discussionmentioning
confidence: 99%
“…Supportive data from imaging, neurological-examinations, and biomarkers are valuable adjuncts. Sur1 is a promising and novel target: it has a pathophysiologic basis-its role in a specific pathway of CE is established in animal models(2931), its upregulation is specific to CNS injury and is seen in human contusions(29, 32, 42), and inhibition of this receptor by Glibenclamide in animal models and early clinical trials in ischemic stroke has reduced the development of edema and improved outcomes(2931, 41). …”
Section: Discussionmentioning
confidence: 99%
“…Glibenclamide) had reduced mortality (14% vs 36%, p=0.03) and decreased evidence of cerebral edema determined by midline shift between 72–96 hours (4.4±3.6 mm vs 8.8±4.9 mm, p=0.0006)(41). Sur1 upregulation has also been demonstrated in multiple cell types in human cerebral contusions(42). However, to our knowledge, quantification of human Sur1 in cerebrospinal fluid(CSF) from patients with any CNS injury remains undefined.…”
Section: Introductionmentioning
confidence: 99%
“…Trpm4 forms heterodimers and a functional Sur1-Trpm4 channel that antagonizes calcium influx mediated by receptor operated calcium entry (ROCE) cation channels 35 . This ion channel is not expressed constitutively but is transcriptionally upregulated in microglia and astrocytes 36 in responsive to various neuroinflammatory brain conditions including traumatic brain injury (TBI) 37 , subarachnoid hemorrhage (SAH) [38][39][40] , and neuroinflammatory conditions such as multiple sclerosis (MS)/experimental autoimmune encephalomyelitis (EAE) 21,41 . Thus, the Sur1-Trpm4 channel is a key neuro-regulator involved in various neurological disorders including brain injuries and neurodegeneration 5,20 .…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, it is possible that Sur1-Trpm4 channel-induced neuropathological effects are responsible for the Vpr effects or are part of the collective induction of Vpr-induced HAND. If this is true, this finding might be clinically significant because the Sur1-Trpm4 channel has shown to be a key drug target of various neuroinflammatory conditions 21,[37][38][39][40][41] , and pharmacologic inhibition of this channel by the repurposed and FDA-approved drug glibenclamide significantly improved clinical outcomes of those neurologic disorders 21,[42][43][44][45] . Indeed, the Sur1 inhibitor glibenclamide suppresses Vpr-induced apoptosis in a concentration-dependent manner (Fig.…”
Section: Discussionmentioning
confidence: 99%